Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:118636371" >
Long-term outcomes ...
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
-
Treon, SP (författare)
-
Branagan, AR (författare)
-
Ioakimidis, L (författare)
-
visa fler...
-
Soumerai, JD (författare)
-
Patterson, CJ (författare)
-
Turnbull, B (författare)
-
Wasi, P (författare)
-
Emmanouilides, C (författare)
-
Frankel, SR (författare)
-
Lister, A (författare)
-
Morel, P (författare)
-
Matous, J (författare)
-
Gregory, SA (författare)
-
- Kimby, E (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- American Society of Hematology, 2009
- 2009
- Engelska.
-
Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 113:16, s. 3673-3678
- Relaterad länk:
-
https://europepmc.or...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m2 per day for 5 days) of fludarabine and 8 infusions (375 mg/m2 per week) of rituximab. A total of 43 patients were enrolled. Responses were: complete response (n = 2), very good partial response (n = 14), partial response (n = 21), and minor response (n = 4), for overall and major response rates of 95.3% and 86.0%, respectively. Median time to progression for all patients was 51.2 months and was longer for untreated patients (P = .017) and those achieving at least a very good partial response (P = .049). Grade 3 or higher toxicities included neutropenia (n = 27), thrombocytopenia (n = 7), and pneumonia (n = 6), including 2 patients who died of non–Pneumocystis carinii pneumonia. With a median follow-up of 40.3 months, we observed 3 cases of transformation to aggressive lymphoma and 3 cases of myelodysplastic syndrome/acute myeloid leukemia. The results of this study demonstrate that fludarabine and rituximab are highly active in WM, although short- and long-term toxicities need to be carefully weighed against other available treatment options. This study is registered at clinicaltrials.gov as NCT00020800.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Blood
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Treon, SP
-
Branagan, AR
-
Ioakimidis, L
-
Soumerai, JD
-
Patterson, CJ
-
Turnbull, B
-
visa fler...
-
Wasi, P
-
Emmanouilides, C
-
Frankel, SR
-
Lister, A
-
Morel, P
-
Matous, J
-
Gregory, SA
-
Kimby, E
-
visa färre...
- Artiklar i publikationen
-
Blood
- Av lärosätet
-
Karolinska Institutet